Prosorba column information

[Guest guest]

About the Prosorba column from the manufacturer:

" The Prosorba Column Treatment " :

http://www.freseniushc.com/rheumatoid/prosorba.html

" Rheumatoid Arthritis Immunoadsorption Column " :

http://www.freseniushc.com/product/raphysician.html

FAQ:

http://www.freseniushc.com/product/prosorbafaq.html

***********************

Aetna

Clinical Policy Bulletins

Number: 0355

" Subject: Extracorporeal Immunoadsorption (Prosorba column) " :

http://www.aetna.com/cpb/data/CPBA0355.html

***********************

Rheuma21st

February 20-24, 2002

" Novel Aspects in Autoimmunity and Autoimmune Diseases:

Immunoadsorption Therapies in Autoimmunity " :

In his opening lecture " The Rationale for Immunoadsorption - from Stone

Age to Platin Age, " U. Nydegger (Switzerland) presented the development

from unselective extracorporeal removal of plasma compounds by

therapeutic plasma-exchange (TPE) toward highly specific extracorporeal

immunoadsorption (EIA) with synthetic mimicking peptides used as

ligands. The advantages of these specific adsorber systems, e.g.

improved efficacy, will allow better therapeutic strategies for patients

with autoimmune diseases in the future. Nydegger also pointed out that

clear evidence on the benefits of this treatment has been established.

P. Kern summarised data of EIA in rheumatic diseases, e.g. SLE and RA.

The clinical efficacy of Protein-A Immunoadsorption (PA-IA) (Prosorba)

in patients with refractory RA was shown in a sham-controlled pivotal

study and is comparable with newer results from TNF-alpha inhibitors. A

clear rationale for successful PA-IA treatment (Immunosorba) of diseases

caused by defined and specific pathogenic antibodies was demonstrated by

D. Zillikens (Würzburg, Germany) for pemphigus foliaceus and pemphigus

vulgaris and by B.M. Taleghani (Bern, Switzerland) for the treatment of

non-haemophilic patients with factor VIII inhibitors. EIA systems with

amino acid (Phe or Trp) linked to polyvinyl alcohol-gel (Immusorba) were

successfully used in the treatment of SLE and Wegener`s granulomatosis

as data presented by A. Armuss (München, Germany) showed.

http://www.rheuma21st.com/archives/report_shoenfeld_3int_cong_autoinmun.html

***********************

" Protein A immunoadsorption in therapy refractory rheumatic diseases -

preliminary clinical experiences " :

http://www.dialysis-north.de/presents/akzoshow.htm

(very good slide show!)

***********************

I'll tell you where to go!

Mayo Clinic in Rochester

http://www.mayoclinic.org/rochester

s Hopkins Medicine

http://www.hopkinsmedicine.org